Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 6/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6821538 | 0.98 | LTA4H (0.50) | LTA4HGAAMGAMSIMGAM2 | |
| SCHEMBL2213689 | 0.94 | GAA (0.48) | LTA4HGAAMGAMSIMGAM2 | |
| SCHEMBL285776 | 0.86 | LTA4H (0.50) | LTA4HGAAMGAMSIMGAM2 | |
| SCHEMBL1632531 | 0.86 | GAA (0.52) | LTA4HGAAMGAMSIMGAM2 | |
| SCHEMBL1392816 | 0.85 | LTA4H (0.51) | LTA4HGAAMGAMSIMGAM2 | |
| SCHEMBL22689618 | 0.85 | LTA4H (0.51) | LTA4HGAAMGAMSIMGAM2 | |
| SCHEMBL7442865 | 0.85 | GAA (0.55) | LTA4HGAAMGAMSIMGAM2 | |
| SCHEMBL8865384 | 0.85 | LTA4H (0.51) | LTA4HGAAMGAMSIMGAM2 | |
| SCHEMBL6037465 | 0.85 | LTA4H (0.51) | LTA4HGAAMGAMSIMGAM2 | |
| SCHEMBL28210814 | 0.85 | LTA4H (0.51) | LTA4HGAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303527-B1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | disclosed |
| CN-1443190-A | Matrix metalloproteinase inhibitors | LEO PHARM PROD LTD (DK) | 2003-09-17 | — | — | CN | disclosed |
| EP-1303527-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Leo Pharma A/S (DK) | 2003-04-23 | — | — | EP | disclosed |
| US-6521606-B2 | 2-(4-Chlorophenoxy)-2-oxo-1,3,2-oxazaphosphorinane-3-aceto -hydroxamic acid, for example; antiathritic, -tumor, -metastasis, -proliferative and -ulcer agents; multiple sclerosis; vision defects; skin disorders | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2003-02-18 | — | — | US | disclosed |
| US-20020103166-A1 | Matrix metalloproteinase inhibitors | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2002-08-01 | — | — | US | disclosed |
| WO-2002006293-A1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMA A/S (DK) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103166-A1 | Matrix metalloproteinase inhibitors | MMP1, MMP9, MMP8 | LTA4H 1781/4885GAA 2894/4885MGAM 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.